【摘要】 目的通过观察派能达胶囊对慢乙肝肝硬化患者外周血象及症状的影响,探讨其是否可增强抗病毒治疗疗效,为临床慢乙肝肝硬化的治疗提供帮助。方法 60例患者随机分为2组,每组30例,对照组用抗病毒药(拉米夫定100mg/d+阿德福韦酯10mg/d),治疗组加用派能达胶囊(2粒/次,2次/d);派能达胶囊治疗6个月,治疗结束后所有患者继续服用抗病毒药物并随访。比较两组治疗前后的中医证候积分。对病例中伴白细胞减少(<4*109/L)和(或)血小板减少(<100*109/L)的比较治疗前后血细胞水平。结果 1.治疗后,治疗组患者的WBC计数较治疗前升高(P<0.05),对照组患者的WBC计数较治疗前也升高(P>0.05),治疗后治疗组的WBC计数高于对照组(P<0.05);2.治疗后2组血小板计数较前均有升高,但同组治疗前后比较无统计学差异,两组间比较治疗前后PLT计数也无统计学差异;3.2组治疗后证候积分均下降(P<0.05),且治疗后治疗组积分低于对照组(P<0.05)。结论派能达胶囊联合抗病毒治疗可提高抗病毒疗效,改善慢乙肝肝硬化患者血细胞减少症,改善患者临床症状,提高生活质量。更多还原

【Abstract】 Objective To observe the effect of Painengda on peripheral blood cell count and symptoms of patients with Chronic Hepatitis B and Liver fibrosis,explore whether can it strengthen the curative effect of nucleoside analogues,and help in treatment of Chronic Hepatitis B and Liver fibrosis. Methods The selected 60 patients were randomly assigned to two Groups(30patients in each group),the control group were treated by nucleoside analogues(Lamivudine 100 mg and Adefovir 10 mg once a day)while the treated group were treated by nucleoside analogues(the same as the control group)and Painengda,which dose was 2 pills twice a day. After 6 months,the treatment of Painengda was stopped,the treatment of nucleoside analogues going on in both of the groups. Then compared syndrome integral of two groups and compared the peripheral blood cell count of patients with low level of WBC(<4×109/L)and(or)PLT(<100×109/L). Results 1. The WBC level in the treated group was obviously enhanced than in the control group(P<0.05);2. The PLT level raised in each group after therapy,but there were no statistical differences in each group itself or between the two groups;3. The syndrome integral decreased in both of the two groups after treatment(P<0.05),while the treated group’s lower(P<0.05). Conclusion Painengda can improve the curative effect of nucleoside analogues,increase the count of WBC and PLT and improve the clinical symptoms,creating a better quality of life.更多还原